
|Articles|October 22, 2021
In case you missed it: Oct. 18 to Oct. 22
Author(s)Lindsey Carr, Editor
It's been a busy week for the Contemporary OB/GYN® team.
Advertisement
Here's what you missed this week:
Diagnosing and treating vaginal discharge
S3E18: Coping with COVID-19
Poll: What content would you like to see more of from Contemporary OB/GYN®?
New risk factors for vulvovaginal candidiasis and recurrence
FDA approves flu vaccine for children as young as 6 months
Advertisement
Related to this article

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.

Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.

Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.

A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.

Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.

The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Reactions to FDA's boxed warning removals for menopausal hormone therapy
2
Top headlines in women's health from October 2026
3
Top video interviews from The Menopause Society 2026 Annual Meeting
4
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
5

